Showing results (141-150 of 233) with videos related to

Sort By:
Pageof 24
Research and Practice in Thrombosis and Haemostasis|September 2, 2024
Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpuraKaterina Pavenski, Marie Scully, Paul Coppo, et al.
Frontiers in Immunology|July 10, 2024
A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITLLaure Ricard, Pascale Cervera, Nicolas Stocker, et al.
Haematologica|November 2, 2020
Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpuraNuno A G Graça, Bogac Ercig, Leydi Carolina Velásquez Pereira, et al.
Scandinavian Journal of Immunology|December 8, 2021
Overexpression of IgG2 in patients resembling IgG4-related disease with normal IgG4Mathilde Lecuit, Pierre Aucouturier, Aicha Abbas, et al.
Blood Advances|September 24, 2021
Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTPLaure De Waele, Alexandre Curie, Kadri Kangro, et al.
Blood Advances|April 21, 2021
Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysisFlora Peyvandi, Spero Cataland, Marie Scully, et al.
Pageof 24